Insulin Glulisine

Authors: Robinson, Dean M.; Wellington, Keri

Source: Drugs, Volume 66, Number 6, 2006 , pp. 861-869(9)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

▴ Insulin glulisine is a rapid-acting human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin (RHI) in patients with type 1 or 2 diabetes mellitus and is efficacious in controlling prandial blood glucose levels in these patients.

▴ In large, well designed trials in patients with type 1 diabetes, insulin glulisine demonstrated a similar degree of glycaemic control, as measured by glycosylated haemoglobin (HbA_1c) levels, to RHI after 12 weeks and insulin lispro after 26 weeks.

▴ Pre-meal insulin glulisine was also more effective than RHI at controlling 2-hour post-prandial glucose excursions in patients with type 1 or 2 diabetes over a period of 12 weeks.

▴ In patients with type 2 diabetes, insulin glulisine induced significantly greater reductions in HbA_1c levels and 2-hour post-breakfast and post-dinner blood glucose levels than RHI over a period of 26 weeks.

▴ Insulin glulisine was generally well tolerated by patients with type 1 or 2 diabetes and had a similar safety profile to insulin lispro or RHI. Severe hypoglycaemia was experienced by similar proportions of insulin glulisine or comparator insulin (insulin lispro or RHI) recipients with type 1 or type 2 diabetes.

Keywords: Adis Drug Profiles; Diabetes mellitus; Insulin glulisine; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Document Type: Research article

Affiliations: 1: Adis International Limited, Auckland, New Zealand

Publication date: 2006-01-01